Utama › Leukemia › Illinois › Chicago
Kajian klinikal Leukemia di Chicago, IL
16 kajian untuk Leukemia sedang mencari peserta di lokasi dalam dan sekitar Chicago (dalam lingkungan kira-kira 30 batu). Buka kajian untuk melihat siapa yang layak menyertai dan cara menghubungi pasukan kajian.
Teks kajian rasmi (Bahasa Inggeris)
Mengambil peserta untuk kajian di sini? Paparkan di bahagian atas halaman ini — $99 selama 30 hari →
A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation
Mengambil pesertaFasa 1/2
- The University of Chicago Medical Center, Chicago
Surovatamig as Consolidation Therapy in Participants With Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma With Unmutated Immunoglobulin Heavy Chain Variable (IGHV)
Mengambil pesertaFasa 3
- Research Site, Chicago
Study of Allo-QuadCAR01-T, an Allogeneic CAR-T Targeting CD19/CD20, in Patients With Relapsed or Refractory B-Cell Malignancies
Mengambil pesertaFasa 1/2
- University of Chicago, Chicago
Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia
Mengambil pesertaFasa 1
- Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago
Caloric Restriction and Activity to Reduce Chemoresistance in B-ALL
Mengambil pesertaFasa 2
- Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago
AZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia
Mengambil pesertaFasa 1/2
- Research Site, Chicago
Mosaic Trial for Stem Cell Transplant Recipients
Mengambil peserta
- Northwestern University Feinberg School of Medicine, Chicago
Study of Chemotherapy-Free Induction Regimen for Ph+ Acute Lymphoblastic Leukemia With Inotuzumab Ozogamicin (InO)
Mengambil pesertaFasa 2
- University of Chicago Medical Center, Chicago
Effects of Dexrazoxane Hydrochloride on Biomarkers Associated With Cardiomyopathy and Heart Failure After Cancer Treatment
Mengambil pesertaKajian pemerhatian
- Lurie Children's Hospital-Chicago, Chicago
The OPAL Study: AVM0703 for Treatment of Lymphoid Malignancies
Mengambil pesertaFasa 1/2
- University of Illinois at Chicago Cancer Center, Chicago
A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML
Mengambil pesertaFasa 1
- Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago
Spiritual Care Intervention in Adult Patients Diagnosed With Acute Leukemia
Mengambil peserta
- UChicago Medicine Comprehensive Cancer Center, Chicago
CApivasertib, Venetoclax And Low-intensity chemotheRapY for Adults With ALL/LBL
Mengambil pesertaFasa 1/2
- University of Chicago Medicine Comprehensive Cancer Center, Chicago
Leukemia and Lymphoma Society (LLS) Services Impact on Outcomes and Care
Mengambil peserta
- University of Chicago Comprehensive Cancer Center, Chicago
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Mengambil pesertaKajian pemerhatian
- Massive Bio SYNERGY-AI site, Chicago
A Study of BH-30236 in Relapsed/ Refractory Acute Myelogenous Leukemia and Higher Risk Myelodysplastic Syndrome
Mengambil pesertaFasa 1
- Northwestern Medicine - Northwestern Memorial Hospital Galter Pavilion, Chicago
Kajian Leukemia di bandar lain
- Houston, TX28 kajian
- Boston, MA25 kajian
- New York City, NY19 kajian
- Los Angeles, CA16 kajian
- Durham, NC13 kajian
- Columbus, OH12 kajian
- Nashville, TN12 kajian
- Baldwin Park, CA12 kajian
- Philadelphia, PA12 kajian
- Milwaukee, WI11 kajian
- Atlanta, GA11 kajian
- Seattle, WA11 kajian
Kajian lain di Chicago
- Kanser Paru-paru Bukan Sel Kecil61 kajian
- Kanser Payudara58 kajian
- Kanser (semua jenis)51 kajian
- Kanser Metastatik45 kajian
- Kanser Prostat45 kajian
- Obesiti41 kajian
- Kanser Paru-paru41 kajian
- Kanser Ovari36 kajian
- Strok34 kajian
- Kanser Kolorektal33 kajian
- Kegagalan Jantung31 kajian
- Berat Badan Berlebihan28 kajian
Daripada ClinicalTrials.gov, data diperoleh pada 4 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.